Publications by authors named "Piers Gaunt"

Claim this Profile
D
Development and internal validation of prognostic models for event-free survival in newly diagnosed Ewing sarcoma patients based on routinely collected clinical characteristics from the European randomised controlled trial, EE2012.
Laura Kirton, Richard Riley, Piers Gaunt, Bernadette Brennan, Kym Snell

BMJ Open· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol.
Rita Simões, Sarah Gulliford, Beatrice Seddon, Hakim-Moulay Dehbi, Martin Robinson, Piers Gaunt

BMJ Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.
Paul Nankivell, Piers Gaunt, Claire Gaunt, Julia Sissons, Evaggelia Liaskou

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.
Paul Nankivell, Piers Gaunt, Claire Gaunt, Julia Sissons, Evaggelia Liaskou

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.
Amit Patel, Kristian Brock, Daniel Slade, Claire Gaunt, Anthony Kong, Piers Gaunt

BMC Med Res Methodol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer.
Hisham Mehanna, Piers Gaunt, Anthony Kong, Andrew Hartley, Paul Sanghera

Trials· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.
Penella J Woll, Piers Gaunt, Charlotte Gaskell, Robin Young, Charlotte Benson

Br J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma.
Laura J Forker, Becky Bibby, Lingjian Yang, Brian Lane, Joely Irlam, Piers Gaunt

Br J Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Zeeshaan-Ul Hasan, Ikhlaaq Ahmed, Rubeta N Matin, Victoria Homer, John T Lear, Claire Gaunt, Piers Gaunt

Br J Dermatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial.
Penella Woll, Piers Gaunt, Sarah Danson, Nicola Steele, Samreen Ahmed

Lung Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early phase clinical trials extension to guidelines for the content of statistical analysis plans.
Victoria Homer, Christina Yap, Simon Bond, Jane Holmes, Deborah Stocken, Piers Gaunt

BMJ· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.
Laura Forker, Piers Gaunt, Stefano Sioletic, Patrick Shenjere, Robert Potter

Br J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
David Ferry, Lucinda Billingham, Hugh Jarrett, David Dunlop, Penella J Woll, Piers Gaunt

Eur J Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016;45:76.
Keith Wheatley, Jayne S Wilson, Piers Gaunt, Jerry R Marsden

Cancer Treat Rev· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy.
Matthew J Armstrong, Piers Gaunt, Philip N Newsome

Hepatology· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.
Philip N Newsome, Matthew J Armstrong, Piers Gaunt

Lancet· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull

Lancet· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.
Keith Wheatley, Jayne S Wilson, Piers Gaunt, Jerry R Marsden

Cancer Treat Rev· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.
Matthew J Armstrong, Darren Barton, Piers Gaunt, Diana Hull, Kathy Guo

BMJ Open· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis